<DOC>
	<DOCNO>NCT02171663</DOCNO>
	<brief_summary>The primary objective assessment safety BIBW 2992 assess maximum tolerate dose ( MTD ) . Secondary objective collection overall safety data , antitumor efficacy data , well determination pharmacokinetics pharmacodynamic modulation biomarkers BIBW 2992 .</brief_summary>
	<brief_title>Dose Escalation Study BIBW 2992 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Male female patient confirm diagnosis advance , non resectable / metastatic solid tumor , type historically know express EGFR and/or HER2 , fail conventional treatment , therapy proven efficacy exists , amenable establish form treatment preferably patient breast , colorectal prostate cancer Age 18 year old Life expectancy least three ( 3 ) month Written inform consent give consistent International Conference Harmonization Good Clinical Practice guideline Eastern Cooperative Oncology Group ( ECOG ) performance score 0 , 1 , 2 Patients must resolution prior chemo , hormone , immuno , radiotherapyrelated toxicity CTC Grade &lt; = 1 baseline Patients recover previous surgery The 12 additional patient recruit MTD must also meet follow criterion : Measurable tumor deposit ( RECIST ) one technique ( Xray , CT , MRI ) Active infectious disease Gastrointestinal disorder might interfere absorption study drug chronic diarrhea Serious illness concomitant nononcological disease consider investigator incompatible protocol Patients untreated symptomatic brain metastasis . Patients treat , asymptomatic brain metastasis eligible change brain disease status least eight week , history cerebral edema bleed past eight week requirement steroid antiepileptic therapy Cardiac leave ventricular function rest ejection fraction ≥ CTC Grade 1 Absolute neutrophil count ( ANC ) less 1500 / mm3 Platelet count less 100 000 / mm3 Bilirubin great 1.5 mg / dl ( &gt; 26 μmol / L , SI unit equivalent ) Aspartate amino transferase ( AST ) / alanine amino transferase ( ALT ) great three time upper limit normal ( related liver metastasis great five time upper limit normal ) Serum creatinine great 1.5 mg / dl ( &gt; 132 μmol / L , SI ( Système Internationale ) unit equivalent ) Women men sexually active unwilling use medically acceptable method contraception Pregnancy breastfeed Treatment investigational drug ; chemotherapy , immunotherapy , radiotherapy hormone therapy ( exclude Luteinizing HormoneReleasing Hormone agonist , hormone take breast cancer , bisphosphonates ) participation another clinical study within past four week start therapy concomitantly study Treatment EGFR HER2 inhibit drug within past four week start therapy concomitantly study ( 8 week trastuzumab ) Patients unable comply protocol Active alcohol drug abuse The patient may eligible retreatment previous course finish . The patient eligible follow criterion meet : Patients clinical sign disease progression late Xray , CT MRI reveal progressive disease Cardiac leave ventricular function CTC Grade ≥ 2 time previous course Patients fulfil Exclusion Criteria mention Day 29 previous course Patients recover doselimiting toxicity ( DLT ) 14 day last administration BIBW 2992 previous course . Recovery define return baseline level CTC Grade 1 , whichever high</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>